Skip to main content

How long does it take for Xalkori to work?

Medically reviewed by Carmen Pope, BPharm. Last updated on Oct 24, 2024.

Official Answer by Drugs.com

We can estimate from graphs plotting progression-free survival that Xalkori starts to work within approximately 2 months, but most trials report on how long Xalkori keeps a person’s cancer from getting worse, not how quickly it works. This is called progression-free survival.

When Xalkori was used to treat patients with ROS1+ NSCLC that had spread to other parts of their body:

Note that in this trial Xalkori was not compared to another medication.

Regular scans by your cancer care team will reveal whether your tumor is responding to treatment with Xalkori. Keep taking Xalkori exactly as directed until your healthcare provider tells you to stop.

Xalkori) is an oral prescription medicine used to treat people with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in either a gene called ALK (anaplastic lymphoma kinase) or a gene called ROS1. Xalkori may also be used to treat anaplastic large cell lymphoma (ALCL), a type of blood cancer and unresectable, recurrent, or refractory ALK-positive inflammatory myofibroblastic tumors (IMT) in adults and children over the age of 1 year.

Related questions

References
  • Xalkori (crizotinib). Updated 01/2022. Pfizer Laboratories Div Pfizer Inc. https://www.drugs.com/pro/xalkori.html

Read next

How to pronounce Xalkori?

Xalkori is pronounced “zal-KOR-ee”. Xalkori is the brand name product for crizotinib (pronounced “kriz OH ti nib”), the generic name of the drug. Continue reading

Do I need any blood tests while taking Xalkori?

Yes, you will need blood tests while you take Xalkori to help monitor your liver and kidney function, red and white blood cell counts, and in some cases, your electrolytes or blood sugar levels. Your doctor may also order a blood test to determine if you are pregnant. Continue reading

What cancers are treated with Xalkori?

Xalkori treats three types of cancers with genetic mutations: non-small cell lung cancer (NSCLC), anaplastic large cell lymphoma (ALCL), a type of blood cancer, and (ALK)-positive inflammatory myofibroblastic tumors (IMT). Continue reading

See also:

Related medical questions

Drug information

Related support groups